Silo Pharma, Inc. (SILO)
Silo Pharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Silo Pharma, Inc. (SILO) is a Biotechnology company based in US with a market capitalization of $5M. Revenue grew 0.0% year-over-year and free cash flow was negative at -$4.7M. This page tracks SILO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 3 employees · IPO Jan 8, 2021
Valuation
Valuation & price
$4.61as of Jul 22, 2026· -62.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.80
P/B ratio
Market cap ÷ book equity
No dividend
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$5M
Market cap
0.0%
Revenue growth (YoY)
-1128.9%
Gross margin
-$4.7M
Free cash flow (USD)
-$6.9M
Net debt
Net cash position
127.8%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 14, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- FinancingJul 24, 2026Filing
Securities Registration
- 8-K eventJul 10, 2026Filing
New Filing
- 8-K eventJun 18, 2026Filing
Regained Nasdaq Compliance
- 8-K eventJun 3, 2026Filing
Reverse Stock Split
- 8-K eventJun 1, 2026Filing
Reverse Stock Split
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventApr 2, 2026Filing
Asset Purchase Agreement
Questions
Frequently asked questions
What is Silo Pharma, Inc.'s market cap?
Silo Pharma, Inc. (SILO) has a market capitalization of $5M.
What is SILO's P/E ratio?
A meaningful P/E ratio is not available for SILO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is SILO's price-to-book (P/B) ratio?
SILO trades at 0.80 times book value per share.
Does Silo Pharma, Inc. pay a dividend?
No — SILO did not pay a dividend in its latest reported fiscal year.
Are insiders buying SILO stock?
SEC Form 4 filings show no open-market insider buys at Silo Pharma, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.